Q2 2025 · 13F-HR
Column Group LLCholdings as filed
Filed 2025-08-15 · accession 0000950123-25-008462
$65.7M
Reported value
5
Positions
2025-06-30
Period end
The Brief · Column Group LLC · Q2 2025
AI · grounded in 13F
Column Group LLC established a new position in ORIC valued at $35.9M. The fund also initiated stakes in Surrozen, Inc. for $13.4M and RAPT Therapeutics Inc for $10.6M. Additional new positions include TNYA at $5.7M and RVMD at $1.7K.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 68622P109 | ORIC | ORIC Pharmaceuticals Inc. | $35.9M | 54.7% | 3,540,777 | Common | SOLE |
| 86889P109 | — | Surrozen, Inc. | $13.4M | 20.4% | 1,499,773 | Common | SOLE |
| 75382E109 | — | RAPT Therapeutics Inc | $10.6M | 16.2% | 1,328,613 | Common | SOLE |
| 87990A106 | TNYA | Tenaya Therapeutics, Inc. | $5.7M | 8.74% | 9,400,290 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines Inc | $1,692 | 0.00% | 46 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.